CardioInsight Technologies

company

About

CardioInsight develops the electrocardiographic mapping technology that non-invasively generates images of the heart’s electrical activity.

  • 11 - 50

Details

Last Funding Type
Series C
Last Funding Money Raised
$15M
Industries
Health Care,Medical,Medical Device
Founded date
Jan 1, 2006
Number Of Employee
11 - 50
Operating Status
Active

CardioInsight is commercializing a revolutionary technology called Electrocardiographic Mapping (ECM) that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. ECM non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3-D anatomical data obtained from CT scans. The CardioInsight system reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. The ability of ECM to generate accurate images of the heart's electrical activity and its potential to guide therapy in both cardiac arrhythmias and congestive heart failure has been demonstrated in over 260 patient studies sponsored by the Company.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$28.50M
CardioInsight Technologies has raised a total of $28.50M in funding over 2 rounds. Their latest funding was raised on Nov 11, 2013 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 11, 2013 Series C $15M 1 Medtronic Detail
Mar 14, 2012 Series C $7.50M 1 Medtronic Detail
Feb 3, 2010 Series B $6M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
2
CardioInsight Technologies is funded by 2 investors. Medtronic and Global Cardiovascular Innovation Center are the most recent investors.
Investor Name Lead Investor Funding Round
Medtronic Yes Series C
Global Cardiovascular Innovation Center Series B